Discontinued — last reported Q3 '22
Stryker Acquisitions increased by 109.2% to $136.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 89.2%, from $1.26B to $136.00M. Over 3 years (FY 2021 to FY 2024), Acquisitions shows an upward trend with a 68.7% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $77.00M | $122.00M | $113.00M | $2.56B | $0.00 | $0.00 | $0.00 | $0.00 | $390.00M | $0.00 | $0.00 | $246.00M | $88.00M | $1.26B | $30.00M | $4.75B | $65.00M | $136.00M |
| QoQ Change | — | +58.4% | -7.4% | >999% | -100.0% | — | — | — | — | -100.0% | — | — | -64.2% | >999% | -97.6% | >999% | -98.6% | +109.2% |
| YoY Change | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | -77.4% | — | — | >999% | -26.1% | -89.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.